Merck’s New COVID Drug Is Making News — How Does It Compare to Ivermectin?
In his latest video, John Campbell, Ph.D., compared ivermectin, whose use as a COVID treatment has been widely criticized by mainstream media, with Merck’s new COVID drug, Molnupiravir, which is garnering positive media coverage.
In his latest video, John Campbell, Ph.D., compared ivermectin, whose use as a COVID treatment has been widely criticized by mainstream media, with Merck’s new COVID drug, Molnupiravir, which has been the subject of glowing media attention.
Campbell, a UK-based nurse teacher, cited several studies as he compared the two treatments on the basis of effectiveness, safety and cost. He first turned to a paper in the Austin Journal of Pharmacology and Therapeutics, “Drugs Shown to Inhibit SARS-Cov-2 in COVID-19 Disease: Comparative Basic and Clinical Pharmacology of Molnupiravir and Ivermectin.”
The peer-reviewed paper refers to ivermectin as the most studied “repurposed” medication globally, and notes that it is approved by the U.S. Food and Drug Administration and “classified by the World Health Organization (WHO) as an ‘essential’ broad spectrum antiparasitic, antibiotic, and has demonstrated broad antiviral activity against RNA viruses, including HIV, Zika, MERS and coronavirus.”
“And of course, ivermectin also won the Nobel Prize in 2015,” Campbell said.
According to the paper, Campbell said, Molnupiravir — though still going through trials and safety testing — is believed to “work against seasonal and pandemic flu, MERS, coronavirus and SARS-CoV-2.” The paper’s author noted that Molnupiravir does not inhibit inflammation, whereas ivermectin does.
How do the two drugs compare on cost? Ivermectin is exponentially cheaper than Merck’s new Molnupiraravir.
The cost of a complete five-day course of Molnupiravir is $700 — or $70 per pill. That amounts to a 4,000% markup over what it costs Merck to make the drug.
On effectiveness, Molnupiravir is lacking data. The only publicly available clinical data on Molnupiravir comes from a Merck press statement claiming the new drug is 50% effective against hospitalizations and deaths, when used as an early treatment.
For ivermectin, using publicly available data, Campbell referred to one peer-reviewed study that pegs ivermectin’s effectiveness in early treatment at 62%, and an ongoing meta-analysis which shows ivermectin is 66% effective in early treatment and 86% effective as a prophylactic.
Using VigiBase, a WHO database on pharmaceutical safety data, Campbell showed that out of 3.7 billion doses given of ivermectin there have been only 5,693 reports of adverse events — far fewer, according to Campbell, than the number of adverse event reports associated with amoxicillin and ibuprofen, both widely used and considered safe.
Comparable safety information for Merck’s Molnupiravir is not yet available, as trials and studies are still ongoing. But Campbell did raise concern about Molnupiravir’s mutagenic properties. He cited the Austin Journal of Pharmacology and Therapeutics paper which states, “there is some concern about the safety of [Molnupiravir’s] NHC-nucleoside triphosphate, which is mutagenic to mammalian cells.”
According to Campbell, Merck denies this is a problem. But the paper suggests, at the very least,” it needs looking into,” Campbell said.
Watch this video
This article (Merck’s New COVID Drug Is Making News — How Does It Compare to Ivermectin?) originated on The Defender and is here by ‘contribution’ with attribution to the articles author Jeremy Loffredo and childrenshealthdefense.org/defender.
Image Credit: Ivermectin Photo in featured image (top) Cropped – From original article
More great articles about Ivermectin
TLB Editors Note: TLB highly recommends you click on the image (the Defender) below, visit this great website, and do whatever you can to help see this vital forum succeed … for the sake of our children !!!
Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. CHD is planning many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured. Your support is essential to CHD’s successful mission.
Stay tuned to …
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.